TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Empowering Veterans to Communicate With Healthcare Providers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (age 18+) English-speaking CKD patients stage 3 (eGFR = 30-70 mL/min) who are scheduled for a clinic visit will be eligible for participation.~   1. Up to 60 will receive the QPS and all data collection activities~  2. Up to 10 will be audio recorded only~2. Nephrologists (or Nurse Practitioners or Physician Assistants) seeing CKD patients in routine clinic visits will be eligible for participation at Hines, VA.~Exclusion Criteria:~1. CKD patients who are non-English speaking, blind, hard of hearing or deaf, unable to read, and/or who are cognitively impaired will not be eligible for participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CKD-Question Prompt Sheet (Type: EXPERIMENTAL): Study participants will receive the CKD-QPS.
- Control (Type: NO_INTERVENTION): Individuals will not receive any intervention or surveys.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diastolic Exercise Stress Testing in Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Unclear etiology of dyspnea with non-invasive testing~* HFA-PEFF score 2-4 points and thus an intermediate risk for HFpEF~* Willingness to participate and obtained written consent~Exclusion Criteria:~* Consent for study participation not obtained~* Age \< 18 years~* Medical contraindications to perform right heart catheterization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with intermediate risk for HFpEF at rest (Type: None): Patients with a HFA-PEFF score of 2-4 points and no obvious extracardiac explanation for exercise-induced dyspnea. Right heart catheterization with be performed at rest and during stress testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Written ICF signed voluntarily before the first trial related activity.~2. Subjects with a history of GERD symptoms (i.e., heartburn and/or regurgitation) during the last 6 months~3. Subjects on a stable dose of PPIs, compliant for at least 6 weeks prior to screening.~4. ≥3 days per week with heartburn and/or regurgitation symptoms of at least moderate severity and a minimum of 25 liquid containing reflux events over 24h (pH/MII monitoring).~Exclusion criteria:~1. Subjects with prior endoscopic anti-reflux procedure or major GI surgery or subjects with major GI disorders.~2. Presence of severe and clinically uncontrolled cardiovascular, liver or lung disease, neurologic, cancer or AIDS.~3. Alarm symptoms suggestive of malignancies or organic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SPD557 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female between 18-80 years old (including patients aged 18 and 80)~2. Subjects capable of giving informed consent~3. Patients carrying the diagnosis or symptomatic sterile or infected walled-off pancreatic necrosis (WOPN) based upon Atlanta Classification (4) ≥ 4cm in largest diameter, deemed to require and amenable to endoscopic transmural drainage with or without necrosectomy by attending gastroenterologist~4. Fluid collection size ≥ 4cm in largest diameter (based on CT, MRI, transabdominal or endoscopic ultrasound within 30days)~5. Fluid collection that is adherent to the stomach/bowel wall allowing for fistula tract creation~6. Fluid collection containing significant amount of necrotic material (defined as \>30% of echogenic material by ultrasound/EUS, or necrotic debris by CT/MRI)~Exclusion Criteria:~1. Inability to provide written informed consent~2. Contraindications to endoscopic treatment as determined by the gastroenterologist attending~3. Pregnant or nursing mothers~4. Bleeding or coagulation disorder~5. Previous surgical or endoscopic cystogastrostomy/enterostomy or necrosectomy~6. Shock~7. Cystic neoplasms or pancreatic malignancy~8. Pseudocysts~9. Subjects cannot be homeless or incarcerated~10. Age younger than 18 or older than 80~11. More than one pancreatic/peri-pancreatic fluid collection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AXIOS™ stent (Type: ACTIVE_COMPARATOR): 1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
- double pigtail stents (Type: ACTIVE_COMPARATOR): 2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria (not all inclusive):~* Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.~* Subject is 18 to 65 years of age, inclusive, at the time of informed consent.~* Subject meets DSM-5 criteria, based on the SCID-5-CT, for bipolar I disorder, current episode depressed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but \< 8 episodes in the previous 12 months) with or without psychotic features.~* Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration at Screening.~* Subject has a MADRS total score ≥ 22 at both Screening and Baseline.~* Subject has a CGI-BP-S depression score ≥ 4 at both Screening and Baseline.~* Subject has a YMRS total score ≤ 12 at both Screening and Baseline.~* Subject is in good physical health, based on medical history, physical examination, neurological examination, vital signs, ECGs, and results of clinical laboratory tests (hematology, chemistry, and urinalysis).~Exclusion Criteria:~Exclusion Criteria (not all inclusive):~* Subject currently has any DSM-5 defined psychiatric diagnosis other than bipolar I disorder that was the primary focus of treatment, or is currently being treated with concomitant medication~* Subject has a lifetime history of, or symptoms consistent with, schizophrenia, schizoaffective disorder, or a major psychiatric diagnosis other than bipolar I disorder that is judged to pose risk to the study scientific objectives~* Subject has a history of non-response to an adequate (6-week) trial of 3 or more antidepressants (with or without mood stabilizers) during the current major depressive episode.~* Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that would pose a risk to the subject or that might confound the results of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SEP-4199 CR 200 mg (Type: EXPERIMENTAL): SEP-4199 CR 200 mg/day
- SEP-4199 CR 400 mg (Type: EXPERIMENTAL): SEP-4199 CR 400 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Shear Wave Elastography in Native Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients over 18 years of age who are referred for a native kidney biopsy.~Exclusion Criteria:~* BMI \> 35~* Patients with polycystic kidney disease, renal cell carcinoma, hydronephrosis or renal stones.~* Patients who develop severe post biopsy complications (infection, significant bleeding requiring transfusion or intervention)~* Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shear wave elastography group (Type: EXPERIMENTAL): Patients referred for kidney biopsy will then undergo shear wave elastography measurements.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Lumbar-spine Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Key- Inclusion Criteria:~1. Male or female \>30 years of age~2. Lumbar spine pathology with indication for monosegmental PLIF~3. Radiological signs of a degeneration of the adjacent segment without instability~Key Exclusion Criteria:~1. Radiological signs of existing instability of the adjacent segment~2. Normal endplates and no disc desiccation in MRI in the adjacent seg-ment~3. Previous surgery of the lumbar spine

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hybrid system (Type: EXPERIMENTAL): hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
- Plif posterior lumbar intervertebral fusion (Type: ACTIVE_COMPARATOR): Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~This protocol is open to male and female patients of all races with a diagnosis of severe sickle hemoglobinopathy providing they also satisfy the following eligibility criteria:~* Adult and pediatric patients with Hb SC disease who are able to swallow the Mg pidolate preparation and who have had at least one prior painful crisis.~Exclusion Criteria:~* Patients transfused within 90 days of study entry,~* Patients with elevated (\>1.5 times upper limit of normal for age) BUN, creatinine, or liver function tests \> 3 times the upper limit of normal for age,~* Patients who take a magnesium-containing medication (Mylanta, Maalox, etc.) on a regular (i.e., more than 2 days per week) basis.~* Patients with progressive neuromuscular disease or patients who are treated with a calcium channel blocker.~* Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment.
- MG Pidolate Administration (Type: ACTIVE_COMPARATOR): A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Home-based AIDS Care Project

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* CD4 cell count \<250 or symptomatic AIDS~* Age \>13 years~* Karnofsky score \>40%~* AST or ALT \< 5 times normal values~* Creatinine clearance \>25 ml/min

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone in Borderline Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In- and Outpatients:Borderline personality disorder according to the Diagnostic and Statistical Manual for Mental Disorders, 4.Edition (DSM IV)~* DES-(Dissociative Experience Scale)-score: \> or equal 18 according to amendment4 (former value according to amendment 2 was \> or equal 25).~* Urinary test of opiates negative~* No psychopharmacological treatment for two weeks prior to study (fluoxetine four weeks)~* No Lithium for two months~Exclusion Criteria:~* Lifetime diagnosis of psychotic disorder~* Current major depressive disorder (MDD)~* Lifetime diagnosis opioid dependence or current opioid abuse (10 to 7 days prior to study)~* Comedication with opioid analgetics~* Known naltrexone intolerance~* Liver disease~* Pregnancy and lactation period~* Other severe medical or neurological diseases~* Simultaneous participation in another study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
- 2 (Type: OTHER): Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
- 3 (Type: OTHER): Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
- 4 (Type: OTHER): Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female; Age: 18Y or older.~* Pre-menopausal.~* FSH level is less than 10 mIU/L.~* Have at least moderate uterine fibroid-related symptoms (score of 24 or higher according to UFS-QOL questionnaire.~* Have a total uterine volume greater than or equal to 160 cc by ultrasound measurement and at least one fibroid that is ≥ 2.5cm in diameter.~* Agree to use a double-barrier method (condoms, diaphragms) or other effective non-hormonal methods of contraception (abstinence, sterilization) throughout participation in the study to prevent pregnancy.~* Agree to report any pregnancy to the research staff immediately.~* Willing and able to give informed consent.~* Willing and able to comply with study requirements.~* Liver function (ALT, AST, Prothrombin time and concentration)to be≤ 1.5 times the upper limit of normal~Exclusion Criteria:~* Current or planned pregnancy during the study period.~* Menopausal, as indicated by elevated follicle stimulating hormone (FSH) serum level.~* Currently breast-feeding.~* Untreated abnormal pap smear.~* Presence of conditions other than fibroids contributing to pelvic pain and/or bleeding;~* Hemoglobin \< 8.0 mg/dl.~* Presence of adnexal masses or tenderness indicating the need for further evaluation or surgery.~* Grade III or IV hydronephrosis by ultrasound.~* Mental health disorder.~* Active substance abuse or dependence.~* Current or recent (within the past 3 months) use of the following medications: Oral or systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, Herbal or botanical supplements with possible hormonal or EGCG effects. Use within the past six months of the gonadotropin releasing hormones (GnRH) analogs or Depo-Provera,~* Current or planned use during the study of any of the following medications/or products: ketoconazole, itraconazole, erythromycin, grapefruit juice, rifampin, St John's Wort, phenytoin, phenobarbital, or carbamazepine.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EGCG ( Green Tea extract) (Type: ACTIVE_COMPARATOR): 40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
- Brown Rice pills (Type: PLACEBO_COMPARATOR): 40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Relaxation and Visualization Therapy for Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women who have been diagnosed with breast cancer and have been referred to radiotherapy at OHSU~* between 45 and 70 years of age~Exclusion Criteria:~* receiving chemotherapy concurrently~* uses tobacco products~* has a fear or aversion to blood draws~* has a history of hypertension~* uses recreational drugs~* drinks more than 3-5 alcoholic beverages per week~* takes any anti-inflammatory medications~* has a current infection or has a compromised immune system

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Relaxation and Visualization Therapy group
- B (Type: ACTIVE_COMPARATOR): Health education group
- C (Type: NO_INTERVENTION): Control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues